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Abstract The efficacy and safety of telavancin is under eval-
uation for the treatment of subjects with complicated
Staphylococcus aureus bacteremia and S. aureus right-sided
infective endocarditis. This study evaluated the telavancin ac-
tivity against a global collection of S. aureus causing blood-
stream infections (BSI), including endocarditis, to support the
development of bacteremia/endocarditis clinical indications.
This study included a total of 4191 S. aureus [1490
methicillin-resistant S. aureus (MRSA)], which were unique
(one per patient) clinical isolates recovered from blood sam-
ples collected during 2011–2014 in a global network of hos-
pitals. All isolates were deemed responsible for BSI, including
endocarditis, by local guidelines. Isolates were tested for sus-
ceptibility by broth microdilution. Telavancin (MIC50/90, 0.03/
0.06 μg/ml) inhibited all S. aureus at ≤0.12 μg/ml, the
breakpoint for susceptibility. Equivalent minimum inhibitory
concentration (MIC) values (MIC50/90, 0.03/0.06 μg/ml) were
obtained for telavancin against methicillin-susceptible
S. aureus (MSSA) andMRSA isolates, as well asMRSA from
community and healthcare origins. Similar telavancin activi-
ties (MIC50, 0.03 μg/ml) were observed against MRSA sub-
sets from North America and Europe, while isolates from the
Asia-Pacific (APAC) and Latin America regions had MIC50
values of 0.06 μg/ml. MRSAwith vancomycin MIC values of
2–4 μg/ml and the multidrug resistance (MDR) subset had
telavancin MIC50 results of 0.06 μg/ml, although the MIC100
result obtained against these subsets remained identical to
those of MSSA (MIC100, 0.12 μg/ml, respectively). This
study updates the telavancin in vitro activity, which continues
to demonstrate great potency against invasive S. aureus, re-
gardless of the susceptibility phenotype or demographic char-
acteristics (100.0% susceptible), and supports the sought-after
subsequent indications.
Introduction
Staphylococcus aureus is the second most common cause of
bloodstream infection (BSI), and is the most important cause
of BSI-associated death [1]. Prevalence-based studies, such as
the SENTRYAntimicrobial Surveillance Program, observed a
rate of 44.3% of S. aureus [45.4% methicillin-resistant
S. aureus (MRSA)] causing bacteremia in USA hospitals dur-
ing the 2015 sampling year (unpublished JMI data). Among
multicenter and population-based investigations, incidence
rates of 15–40 per 100,000 population per year have been
identified, with case-fatality rates of approximately 15–25%
[1–3].
Telavancin is a once-daily parenteral semi-synthetic
lipoglycopeptide agent approved in the United States,
Europe, and Canada for clinical indications, such as compli-
cated skin and skin structure infections and/or hospital-
acquired and ventilator-associated bacterial pneumonia (see
package inserts for a complete description of respective indi-
cations) [4]. The efficacy and safety of telavancin is also under
evaluation for the treatment of subjects with complicated
S. aureus bacteremia and S. aureus right-sided infective endo-
carditis (NCT02208063) [5]. The in vitro activity of
telavancin has been monitored and reported previously.
However, this study evaluated the telavancin activity against
a recent and global collection of S. aureus bacteremia isolates,
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including those responsible for endocarditis, to support the
sought-after bacteremia/endocarditis clinical indications.
Materials and methods
This study included a total of 4191 S. aureus (1490 MRSA),
which were unique (one per patient) clinical isolates recovered
from blood samples collected during 2011–2014 in a global
network of hospitals in the North America (2150 isolates),
Europe (1283), Latin America (473), and Asia-Pacific
(APAC; 285) regions. All isolates were deemed responsible
for BSI, including endocarditis, by the participating site ac-
cording to local guidelines. Isolates that met the protocol se-
lection criteria had the bacterial identification initially per-
formed by the participating laboratory, which submitted iso-
lates to a central monitoring laboratory (JMI Laboratories,
North Liberty, IA, USA), as part of the SENTRY
Antimicrobial Surveillance Program. Bacterial identification
was subsequently confirmed by the reference monitoring lab-
oratory by standard algorithms. Isolates showing questionable
phenotypic and/or biochemical results had the bacterial iden-
tification confirmed by matrix-assisted laser desorption/
ionization time-of-flight mass spectrometry (MALDI-TOF-
MS; Bruker Daltonics, Bremen, Germany).
Isolates were tested for susceptibility by broth
microdilution following the Clinical and Laboratory
Standards Institute (CLSI) M07-A10 document [6].
Testing was performed using panels manufactured by
Thermo Fisher Scientific (Cleveland, OH, USA). These
validated panels provide minimum inhibitory concentra-
tion (MIC) results equivalent to the CLSI-approved broth
microdilution method, which includes 0.002% polysor-
bate 80 in the testing media [6]. Bacterial inoculum den-
sity was monitored by colony counts to assure an ade-
quate number of cells for each testing event. Quality of
the MIC values was assured by concurrent testing of
CLSI-recommended quality control (QC) reference strains
Table 1 Antimicrobial activity and minimum inhibitory concentration (MIC) distributions for telavancin when tested against Staphylococcus aureus
clinical isolates, as part of the international telavancin surveillance program
S. aureus/Parameter (number tested) MIC (μg/ml) Number (cumulative %) inhibited at a telavancin MIC (μg/ml) of:
50% 90% ≤0.015 0.03 0.06 0.12
All (4191) 0.03 0.06 169 (4.0) 2465 (62.8) 1538 (99.5) 19 (100.0)
Infection type
BSI (4149) 0.03 0.06 166 (4.0) 2444 (62.9) 1520 (99.5) 19 (100.0)
Endocarditis (42) 0.03 0.06 3 (7.1) 21 (57.1) 18 (100.0)
Origin
CA-MRSA (828) 0.03 0.06 24 (2.9) 482 (61.1) 312 (98.8) 10 (100.0)
HA-MRSA (552) 0.03 0.06 15 (2.7) 284 (54.2) 250 (99.5) 3 (100.0)
Phenotype
MSSA (2701) 0.03 0.06 127 (4.7) 1632 (65.1) 938 (99.9) 4 (100.0)
MRSA (1490) 0.03 0.06 42 (2.8) 833 (58.7) 600 (99.0) 15 (100.0)
MDR (569) 0.06 0.06 8 (1.4) 264 (47.8) 285 (97.9) 12 (100.0)
Non-MDR (921) 0.03 0.06 34 (3.7) 569 (65.5) 315 (99.7) 3 (100.0)
Vancomycin MIC ≤1 μg/ml (1439) 0.03 0.06 41 (2.8) 828 (60.4) 561 (99.4) 9 (100.0)
Vancomycin MIC = 2–4 μg/ml (51) 0.06 0.12 1 (2.0) 5 (11.8) 39 (88.2) 6 (100.0)
Region
North America (2150) 0.03 0.06 102 (4.7) 1374 (68.7) 662 (99.4) 12 (100.0)
MRSA (938) 0.03 0.06 30 (3.2) 586 (65.7) 311 (98.8) 11 (100.0)
Europe (1283) 0.03 0.06 52 (4.1) 798 (66.3) 430 (99.8) 3 (100.0)
MRSA (290) 0.03 0.06 10 (3.4) 174 (63.4) 105 (99.7) 1 (100.0)
Latin America (473) 0.06 0.06 13 (2.7) 206 (46.3) 250 (99.2) 4 (100.0)
MRSA (175) 0.06 0.06 1 (0.6) 47 (27.4) 124 (98.3) 3 (100.0)
APAC (285) 0.06 0.06 2 (0.7) 87 (31.2) 196 (100.0)
MRSA (87) 0.06 0.06 1 (1.1) 26 (31.0) 60 (100.0)
BSI bloodstream infection,MSSAmethicillin-susceptible S. aureus,MRSAmethicillin-resistant S. aureus, CA-MRSA community-acquired MRSA, HA-
MRSA healthcare-associated MRSA; the origin of the isolate was defined based on CDC criteria, MDR multidrug resistance, defined as MRSA
(methicillin [oxacillin]-resistant) resistant to three or more drug classes in addition to β-lactam agents
Eur J Clin Microbiol Infect Dis
(S. aureus ATCC 29213 and Enterococcus faecalis ATCC
29212) [6]. All QC results were within published accept-
able ranges [6]. MIC interpretations for comparator agents
were based on the CLSI M100-S26 [7] and European
Committee on Antimicrobial Susceptibility Testing
(EUCAST) [8] criteria, as available. Data analysis was
performed by grouping isolates based on infection type,
geographic region, and community-acquired (CA) and
healthcare-associated (HA) origin based on the Centers
for Disease Control and Prevention (CDC) criteria [9]
and antimicrobial susceptibility phenotype. The latter ap-
plied the oxacillin breakpoint for grouping methicillin-
susceptible (MSSA) and -resistant (MRSA) isolates and
the vancomycin MIC results for segregating S. aureus be-
tween those with vancomycin MIC values of ≤1 or 2–
4 μg/ml. Isolates were also categorized based on
Table 2 Antimicrobial activity of telavancin and comparator agents tested against a global collection of resistant subsets of S. aureus clinical isolates
responsible for bloodstream infections, including endocarditis
Organism (number tested)/antimicrobial agent MIC (μg/ml) % susceptible/% intermediate/% resistanta
Range 50% 90% CLSI EUCAST
MRSA (1490)
Telavancin ≤0.015–0.12 0.03 0.06 100.0 – –b 100.0 – 0.0
Clindamycin ≤0.25–>2 ≤0.25 >2 63.7 0.2 36.1 63.5 0.2 36.3
Daptomycin 0.12–2 0.25 0.5 99.7 – – 99.7 – 0.3
Erythromycin ≤0.12–>16 >16 >16 18.8 2.8 78.4 19.1 0.6 80.3
Gentamicin ≤1–>8 ≤1 >8 87.7 0.4 11.9 87.3 – 12.7
Levofloxacin ≤0.12–>4 >4 >4 24.9 1.5 73.6 24.9 1.5 73.6
Linezolid 0.25–4 1 1 100.0 – 0.0 100.0 – 0.0
Tetracycline ≤0.5–>8 ≤0.5 2 92.3 0.4 7.3 89.6 2.2 8.1
TMP-SMX ≤0.5–>4 ≤0.5 ≤0.5 97.7 – 2.3 97.7 0.1 2.1
Vancomycin 0.25–4 1 1 99.9 0.1 0.0 99.9 – 0.1
MRSA MDR (569)
Telavancin ≤0.015–0.12 0.06 0.06 100.0 – – 100.0 – 0.0
Clindamycin ≤0.25–>2 >2 >2 9.3 0.4 90.3 9.0 0.4 90.7
Daptomycin 0.12–2 0.25 0.5 99.3 – – 99.3 – 0.7
Erythromycin 0.5–>16 >16 >16 0.5 1.6 97.9 0.5 0.5 98.9
Gentamicin ≤1–>8 ≤1 >8 71.9 0.5 27.6 71.5 – 28.5
Levofloxacin ≤0.12–>4 >4 >4 0.9 0.5 98.6 0.9 0.5 98.6
Linezolid 0.25–4 1 1 100.0 – 0.0 100.0 – 0.0
Tetracycline ≤0.5–>8 ≤0.5 >8 89.1 0.0 10.9 84.0 5.1 10.9
TMP-SMX ≤0.5–>4 ≤0.5 ≤0.5 94.6 – 5.4 94.6 0.4 5.1
Vancomycin 0.5–4 1 1 99.8 0.2 0.0 99.8 – 0.2
MRSAwith vancomycin MIC = 2–4 μg/ml (51)
Telavancin ≤0.015–0.12 0.06 0.12 100.0 – – 100.0 – 0.0
Clindamycin ≤0.25–>2 >2 >2 25.5 0.0 74.5 25.5 0.0 74.5
Daptomycin 0.25–2 0.5 1 98.0 – – 98.0 – 2.0
Erythromycin ≤0.12–>16 >16 >16 9.8 2.0 88.2 9.8 2.0 88.2
Gentamicin ≤1–>8 ≤1 >8 72.5 0.0 27.5 72.5 – 27.5
Levofloxacin ≤0.12–>4 >4 >4 13.7 0.0 86.3 13.7 0.0 86.3
Linezolid 0.25–2 1 2 100.0 – 0.0 100.0 – 0.0
Tetracycline ≤0.5–>8 ≤0.5 2 90.2 0.0 9.8 84.3 5.9 9.8
TMP-SMX ≤0.5–>4 ≤0.5 ≤0.5 94.1 – 5.9 94.1 0.0 5.9
Vancomycin 2–4 2 2 98.0 2.0 0.0 98.0 – 2.0
MRSA methicillin-resistant S. aureus, TMP-SMX trimethoprim–sulfamethoxazole, MDR multidrug resistance (defined as MRSA resistant to three or
more drug classes in addition to β-lactam agents)
a Breakpoint criteria according to the CLSI (M100-S26, 2016) and EUCAST, as available
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multidrug resistance (MDR), defined as MRSA isolates
(methicillin [oxacillin]-resistant) resistant to an additional
three or more drug classes (see Table 2 for a complete list
of antimicrobials utilized).
Results and discussion
Overall, S. aureus isolates were 100.0% susceptible to
telavancin and had the highest MIC50, MIC90, and MIC100
results of 0.03, 0.06, and 0.12 μg/ml, respectively.
Equivalent MIC values (MIC50/90, 0.03/0.06 μg/ml) were ob-
tained for telavancin against isolates from different infection
types (i.e., BSI and endocarditis), MSSA and MRSA isolates,
as well as MRSA from CA and HA origins (Table 1).
Telavancin (MIC50/90, 0.03/0.06 μg/ml) had similar potency
against all S. aureus and the MRSA subsets from North
America and Europe. The isolates from the APAC and Latin
America regions had slightly higher MIC50 values (MIC50/90,
0.06/0.06 μg/ml), although the MIC90 and MIC100 results
remained identical to those obtained for the overall MSSA
population (Table 1).
MRSAwith vancomycin MIC values of 2–4 μg/ml and the
MDR subset had telavancin MIC50 results of 0.06 μg/ml,
which was 2-fold higher than the telavancin MIC50 results
(MIC50, 0.03 μg/ml) for the isolates exhibiting vancomycin
MIC values at ≤1 μg/ml or a non-MDR phenotype. Even
though the MIC50 was higher in these resistant subgroups,
telavancin still inhibited all isolates at the susceptible
breakpoint of ≤0.12 μg/ml (Table 1). Daptomycin (MIC50/90,
0.5/1 μg/ml; Table 2) also demonstrated higher MIC results
when tested against MRSA exhibiting vancomycin MIC
values of 2–4 μg/ml compared with those isolates with van-
comycin MIC values of ≤1 μg/ml (data not shown).
Overall, telavancin showedMIC50 results 8-fold lower than
daptomycin (MIC50/90, 0.25/0.5μg/ml) and up to 32-fold low-
er than vancomycin (MIC50/90, 1/1 μg/ml) against bacteremia
MRSA, including those causing endocarditis (Fig. 1 and
Table 2). Similarly, the telavancin MIC results (MIC50/90,
0.06/0.06 μg/ml) were 4- to 8-fold lower than those obtained
by daptomycin (MIC50/90, 0.25/0.5 μg/ml) and 16-fold lower
than vancomycin (MIC50/90, 1/1 μg/ml) against the MRSA
MDR subset (Table 2). When tested against the MRSA subset
displaying decreased susceptibility to vancomycin (MIC, 2–
4 μg/ml), telavancin (MIC50/90, 0.06/0.12 μg/ml) and dapto-
mycin (MIC50/90, 0.5/1 μg/ml) were the most potent agents;
however, telavancin was 8-fold more potent than daptomycin
(Table 2).
Telavancin demonstrated potent in vitro activity against
this contemporary global collection of S. aureus causing bac-
teremia, including resistant subsets and isolates causing endo-
carditis. In addition, telavancin had in vitro potency at least 4-
Fig. 1 Telavancin, daptomycin, and vancomycin minimum inhibitory
concentration (MIC) distributions obtained against all bacteremia
methicillin-resistant Staphylococcus aureus (MRSA). Data are presented
as the cumulative percentage of isolates inhibited at each MIC (μg/ml).
MIC50 differences between drugs are depicted
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fold greater than other clinically available comparator antimi-
crobial agents (daptomycin and vancomycin) recommended
by the current Infectious Diseases Society of America (IDSA)
guidelines for the treatment of bacteremia caused by MRSA
and MDR subsets [10]. These in vitro results support further
investigations of telavancin as a candidate for the treatment of
bacteremia caused by S. aureus and resistant subsets, includ-
ing those isolates responsible for endocarditis [11]. Moreover,
the results obtained for telavancin corroborate those reported
previously and indicate sustained in vitro potency over time
against S. aureus isolates causing infections in hospitals
worldwide [12–14].
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